Quarterly results round-up: a mixed bag for PerkinElmer and S&N
This article was originally published in Clinica
Executive Summary
Healthcare and life sciences firm PerkinElmer has grown its top line by 14% to $479.5m during its second fiscal quarter, but has seen its profit half to $28.6m. The dip in income was mainly due to a pre-tax gain of $25.6m during last year's Q2, related to the purchase of the remaining stake in a joint venture with Danaher's AB Sciex business. Adjusted earnings were up 27% during the most recent quarter, to $0.42 per share.